Jenscare Scientific reported a Q3 2024 runway-filled quarterly performance characterized by ongoing R&D emphasis and a negative bottom line, with key profitability metrics lagging due to heavy development spend and a lack of disclosed quarterly revenue. EBITDA stood at -CNY 44.23 million and net income was -CNY 37.62 million for Q3, with no revenue figure disclosed for the quarter. On a QoQ basis, net income improved from -CNY 51.13 million in Q2 to -CNY 37.62 million in Q3, while YoY comparisons show a substantial narrowing of losses versus the prior year’s Q3 loss of approximately -CNY 98.0 million. The company sits on a cash-rich balance sheet with CNY 605.99 million in cash and equivalents and a net debt position of -CNY 541.57 million, indicating ample liquidity to fund continued R&D and potential regulatory milestones. The lack of revenue visibility underscores Jenscare’s early-stage commercialization trajectory and execution risk surrounding LuXValve and KenValve development, regulatory approvals, and potential partnerships. Given the current liquidity cushion and improving quarterly loss trajectory, the stock remains a high-risk, high-pollow investment until clear clinical or regulatory milestones materialize.